业务进展情况 介入式脑机接口项目已完成技术验证，预计2026年启动首例人体临床试验，2028年提交注册申请，为神 经调控领域创新突破奠定基础。 经济观察网 心玮医疗-B（06609.HK）公布了2026年的经营目标及多项核心业务进展。 公司业绩目标 公司于2026年2月7日公布2026年经营目标，计划全年营收不低于5.4亿元、利润不低于1亿元，凸显对业 绩增长的信心。 产品研发进展 自主研发的自膨式颅内药物洗脱支架注册申请已于2026年1月获国家药监局受理，预计2026年底完成取 证，有望成为全球首款同类产品。同时，弹簧圈等产品预计2026年第一季度获得海外市场认证，加速国 际化布局。 战略推进 公司计划以2025年财务数据于2026年申报科创板上市，目前已进入上市辅导阶段，若成功落地将提升资 本平台流动性。 以上内容基于公开资料整理，不构成投资建议。 ...

Core Viewpoint - The profitability of Xinwei Medical is becoming increasingly clear, with a significant leap in revenue and profit projected for 2025, marking its entry into the profit zone [1][4]. Financial Performance - Xinwei Medical forecasts a revenue of approximately 400 million to 410 million yuan for 2025, representing a growth of about 44% compared to 278 million yuan in 2024 [6]. - The company expects a pre-tax profit of 80 million yuan, a substantial turnaround from a pre-tax net loss of 12 million yuan in 2024, indicating an increase of nearly 800% [6]. - Adjusted pre-tax profit is projected to reach 77 million yuan, showcasing a clear improvement in profitability quality and capability [6]. Product and Market Development - The growth is primarily driven by the collaborative expansion of the entire product line, particularly in the ischemic stroke sector, where new products and technologies have led to a steady increase in market share [7]. - The sales volume of large-caliber suction catheters has seen a 60% year-on-year increase in the first half of 2025, with an expected annual sales growth of over 200% [7]. - In the hemorrhagic stroke sector, the "Great Wall" intracranial stent has achieved rapid commercial sales, covering 200 new cooperative hospitals in the first half of the year, significantly boosting the sales of spring coil products [8]. Cost Management and Operational Efficiency - Xinwei Medical's overall gross margin has rebounded to nearly 70%, while the sales and management expense ratio has decreased by 8 percentage points to 37%, indicating effective cost control [9]. - The financial characteristics of revenue growth, profit increase, and cost reduction suggest that the company has moved away from a financing-dependent growth model to a self-sustaining cycle of product expansion and profitability [9]. Innovation and Long-term Strategy - The acceptance of the self-expanding intracranial drug-eluting stent application by the National Medical Products Administration represents a significant breakthrough in the company's innovation pipeline [11]. - This product addresses critical treatment needs for intracranial atherosclerotic stenosis and is expected to fill a market gap, enhancing the company's competitive edge in neurointervention [11]. - The company is also advancing its brain-machine interface project, which is expected to begin formal clinical trials by the end of 2026, potentially opening new growth avenues [12]. Conclusion - Xinwei Medical's solid profitability, comprehensive product pipeline, leading innovation capabilities, and clear ecological layout constitute its core competitive advantages, gradually gaining market recognition for its investment value [14]. - Short-term growth will be supported by full product line expansion and cost management optimization, while long-term prospects will be bolstered by innovative products and strategic positioning in emerging fields [14].

Summary of the Conference Call for Xinwei Medical Company Overview - **Company**: Xinwei Medical - **Industry**: Brain-Computer Interface (BCI) and Medical Devices Key Points and Arguments Industry and Product Development - Xinwei Medical's BCI technology utilizes an interventional approach, collecting motor cortex signals via internal jugular vein puncture, offering advantages such as minimally invasive procedures, high safety, and strong signal strength comparable to semi-invasive methods [2][3][4] - The BCI product is nearing finalization, with plans for human trials to begin in the second half of 2026, in collaboration with leading hospitals [2][4] - Initial indications for the BCI target patients with upper limb function loss post-stroke, with future plans to expand to ALS and paralysis patients [2][15] Financial Projections - Xinwei Medical anticipates over 400 million CNY in revenue for 2025, with profits between 70 million to 80 million CNY, and a projected revenue growth rate of approximately 35% for 2026 [2][19] - The company expects significant growth in its ischemic thrombectomy balloon catheter segment, with a doubling in revenue, and over 60 million CNY from hemorrhagic aneurysm assist stents [19] Clinical and Regulatory Insights - The company plans to complete preclinical testing and additional animal studies by mid-2026, aiming for human trials by late 2026 [4][6] - Xinwei Medical has received certification for its AI BCI project from the Ministry of Industry and Information Technology, with plans to complete registration by 2028 [4][14] Competitive Landscape - The company’s interventional BCI surgery is similar to traditional stroke surgeries, allowing for a quick learning curve for physicians, with an estimated procedure time of about 30 minutes [16] - Compared to competitors like Neuralink, Xinwei Medical's approach is less invasive and offers a more straightforward operational pathway [5][17] Market Position and Future Outlook - Xinwei Medical is preparing for an IPO application on the A-share Sci-Tech Innovation Board by March 2025, with expectations to complete the review within 6-12 months [3][23] - The company aims to maintain a gross margin of 65%-70% in 2026, with a gradual increase in net profit margin from 15% in 2025 to 25% in the future [19][26] Research and Development Focus - The company is focused on developing a complete product chain in the cerebrovascular field, emphasizing preventive, therapeutic, and rehabilitative products [8] - Xinwei Medical plans to establish a dedicated company for BCI projects to enhance development in this promising field [27] Cost Management - Sales expenses are projected to decrease from 28% to 21%-22% in 2025, with R&D expenses maintained at 9%-10% of revenue [26] Regulatory Environment - The approval process for BCIs is currently evolving, with an expected review period of 9-10 months under the fast-track system [13] Conclusion - Xinwei Medical is positioned to become a leader in the BCI market with a strong focus on innovation, regulatory compliance, and strategic partnerships, aiming for significant growth in the coming years [27]

Core Viewpoint - The establishment of the Yangtze River Delta Brain-Computer Interface (BCI) Industry Innovation Alliance marks a significant step in advancing brain science research and its industrial applications in the region [1] Group 1: Industry Development - The Yangtze River Delta BCI Industry Innovation Alliance consists of 12 member units, aiming to enhance collaboration in the BCI sector [1] - The conference highlighted the importance of BCI as a key to unlocking the mysteries of the brain, with a focus on future industries such as biomedicine [1] - Nantong has implemented policies to accelerate the development of future industries, identifying biomedicine as one of the six main focus areas [1] Group 2: Clinical Research and Applications - Clinical research is identified as crucial for the practical application of BCI technology [1] - The newly formed alliance aims to bridge the gap between technology research and industrial transformation [1] - Collaboration with Jiangsu Provincial People's Hospital will establish a clinical research center to explore new clinical applications for invasive BCI technologies [1]

Core Insights - The first clinical trial of an interventional brain-computer interface (BCI) in China has successfully assisted a stroke patient in regaining partial motor function [1][5] - The interventional BCI technology involves a minimally invasive procedure to implant electrodes via the neck's blood vessels, allowing for the collection of brain signals without the need for open surgery [8][6] - The technology has been integrated into a multi-center clinical trial and is included in the Ministry of Science and Technology's ethical guidelines for BCI research, indicating its potential for treating various motor function disorders [5][9] Technology Overview - The interventional BCI utilizes a titanium alloy stent that is smaller than a human hair, equipped with brain electrodes to capture brain signals [2] - It combines several technologies, including wireless transmission devices for brain signal communication, intelligent algorithms for decoding motor intentions, and synchronized electrical stimulation to enhance recovery efficiency [4][5] - The interventional method offers a balance between the high-quality signals obtained from invasive methods and the safety of non-invasive approaches [8][6] Industry Development - The Chinese government has issued implementation opinions to promote innovation and development in the BCI industry, outlining specific pathways for industrialization [9] - The application scenarios for BCI technology are expanding, moving from laboratory research to clinical applications, with ongoing trials in various hospitals [15] - Despite rapid advancements, the BCI industry faces challenges such as the need for standardized core components, algorithms, and ethical guidelines, as well as the necessity for a comprehensive industry chain layout [16]

Core Insights - The National Healthcare Security Administration (NHSA) has established a pricing mechanism for newly launched drugs and medical devices, specifically supporting the clinical application and pricing of brain-computer interface (BCI) technologies [1][2] - The introduction of standardized pricing for BCI services is expected to facilitate the adoption of these technologies in clinical settings, indicating that BCI technology is nearing clinical usability [3] Industry Developments - Over 100 new pricing items related to medical technologies have been added, including specific fees for invasive and non-invasive BCI procedures [1] - Provinces such as Jiangsu, Zhejiang, and Hubei have published their BCI service pricing, with fees for non-invasive BCI adaptation set at approximately 966 RMB per session, invasive BCI implantation at around 6,600 RMB, and extraction fees ranging from 3,139 to 3,200 RMB [2] - The NHSA's guidelines emphasize the integration of artificial intelligence in rehabilitation, setting a target for AI-assisted rehabilitation services to be implemented nationwide by 2025, which aligns with the development of BCI technologies [2] Market Potential - Analysts predict significant growth in the global BCI medical application market, estimating it could reach $40 billion by 2030 and $145 billion by 2040 [3] - The BCI industry in China is transitioning from laboratory research to commercial application, indicating a high growth potential and the need for long-term investment strategies focused on technology stability and production capabilities [3] Related Companies - MicroPort NeuroScience (02172) has achieved a significant market share in China's neuro-interventional medical device sector, ranking fourth based on 2023 sales revenue [4] - HeartVue Medical-B (06609) successfully completed animal trials for China's first interventional BCI, with expectations of turning a profit by mid-2025 [4] - Nanjing Panda Electronics (00553) is actively developing a multimodal human-computer interaction system based on BCI technology as part of a key provincial research project [4]

Group 1 - The National Healthcare Security Administration (NHSA) has established a pricing mechanism for newly launched drugs and medical devices, including over 100 price items related to new medical technologies, particularly supporting the clinical application and pricing of brain-computer interface (BCI) technology [1][2] - The NHSA issued the "Guidelines for the Pricing of Neurological Medical Services (Trial)" on March 12, which specifically includes pricing items for BCI technologies such as "invasive BCI implantation fee," "invasive BCI removal fee," and "non-invasive BCI adaptation fee" [1][2] - The pricing standardization for BCI projects provides clarity for companies on how to charge, which is expected to facilitate the implementation of new technologies in medical institutions [3] Group 2 - Provinces such as Hubei, Zhejiang, and Jiangsu have announced BCI-related medical service pricing, with fees for non-invasive BCI adaptation set at 966 yuan per session, invasive BCI implantation at 6,600 yuan per session, and invasive BCI removal at 3,200 yuan per session in Jiangsu [2] - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040, indicating significant growth potential in the downstream application market [3] - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in the BCI sector, with MicroPort holding a significant market share in China's neuro-interventional medical device market and Heartway recently completing animal trials for an invasive BCI [4]

Core Insights - The article discusses a groundbreaking intervention using a brain-machine interface (BMI) to assist patients with motor function recovery after a stroke, allowing them to control their movements through thought alone [1][10]. Group 1: Technology Overview - Brain-machine interfaces connect the brain directly to external devices, bypassing peripheral nerves and muscles, which has been a focus of research for years [2]. - The intervention described is the first of its kind to use an invasive BMI for motor function rehabilitation, developed by a team led by Professor Duan Feng from Nankai University [1][4]. - The invasive BMI is implanted in the blood vessels surrounding the motor cortex, improving signal accuracy compared to non-invasive methods while avoiding the risks associated with traditional invasive procedures [4][5]. Group 2: Clinical Trials and Results - The team conducted successful animal trials before moving to human clinical trials, demonstrating the safety and efficacy of the invasive BMI [5][6]. - The first human trial involved a 67-year-old stroke patient who was able to perform tasks like grasping and manipulating objects with the assistance of the BMI [10]. - The BMI was implanted for several days without complications, and the patient showed improved control over their movements, indicating the potential for significant rehabilitation outcomes [10]. Group 3: Future Implications - The research aims to provide new treatment options for various motor function disorders, including stroke sequelae, spinal cord injuries, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [10]. - The increasing prevalence of stroke in China highlights the urgent need for innovative rehabilitation technologies like the BMI [10]. - Several hospitals across the country are beginning to establish clinical research units for BMIs, indicating a growing interest and investment in this technology [10].

Core Insights - The article emphasizes the mission of scientists and technology workers to advance science and technology in alignment with the "four orientations": global technological frontiers, economic main battlefields, national major needs, and people's health [1][4] Group 1: Technological Advancements - Recent technological progress showcases the commitment of scientists to the "four orientations," with significant achievements in space exploration and quantum technology [2] - The successful zero-height escape flight test of the "Dream Boat" manned spacecraft marks a new milestone in spacecraft development [2] - The first superconducting quantum computing measurement and control system designed for a thousand-bit scale has been delivered to multiple research and industry units, providing over 5000 bits of measurement and control services [2] Group 2: Innovations in Chemical and Energy Sectors - Researchers have developed a new catalyst that directly synthesizes para-xylene from carbon dioxide and hydrogen, expanding new pathways for carbon utilization [2] - A student team from Dalian University of Technology has overcome key technical bottlenecks in perovskite solar cells, creating a new type of battery with high efficiency and stability, suitable for energy supply in near-space vehicles [2] Group 3: Focus on Health and Social Development - The Comprehensive Research Facility for Fusion Technology (CRAFT) has made significant progress, with its low-noise current drive system passing expert testing and acceptance [3] - The first major technological equipment project in the energy sector, a 300 MW variable-speed pumped storage motor's full-size AC collector system, has successfully completed verification tests, filling a gap in domestic manufacturing [3] - Scientific research increasingly targets major public health issues, with breakthroughs in anti-aging stem cell therapy and brain-machine interface technology aiding in the recovery of motor functions in patients [3]

Core Insights - The article discusses a groundbreaking brain-machine interface surgery conducted by a team of experts, aiming to restore motor functions in a paralyzed patient [2][3][4] - The surgery involved the insertion of an electrode chip through blood vessels into the patient's brain, marking a significant advancement in the field of neurotechnology [2][6] - The patient showed improvement in grip strength post-surgery, highlighting the potential of brain-machine interfaces in rehabilitation [2][11] Group 1: Surgical Procedure - The surgery was led by Lin Zhixiong, with collaboration from other experts, focusing on patient selection, safety, and electrode placement [3][4] - The procedure was performed on a 67-year-old male patient suffering from paralysis due to a cerebral infarction, who had previously undergone ineffective conventional treatments [4][9] - The surgery was completed successfully, with the only complication being a temporary spike in the patient's blood pressure post-operation [4][5] Group 2: Technological Context - The article outlines three main types of brain-machine interface technologies: invasive, non-invasive, and interventional, with the latter being the focus of this study [6][7] - The interventional approach allows for the device to be delivered through blood vessels, which is less invasive than traditional methods [6][7] - The technology is still in its early stages, and further clinical trials are necessary to evaluate its effectiveness and safety [7][8] Group 3: Patient Selection and Challenges - Strict criteria were established for patient selection, requiring that conventional rehabilitation methods had failed and that the patient had a specific type of paralysis [8][9] - The recruitment process was challenging, with many potential candidates either not meeting the criteria or declining participation due to the lack of precedent for such surgeries in China [8][9] - The successful recruitment of a suitable patient was a significant milestone for the research team [8][9] Group 4: Rehabilitation and Future Goals - Post-surgery, the patient began rehabilitation training, with the goal of achieving basic self-sufficiency in daily activities [9][11] - The research team aims to enhance neural plasticity and improve motor functions through a combination of brain-machine interface technology and functional electrical stimulation [11] - The long-term objective is to enable patients to regain independence and improve their quality of life through advanced neurotechnological interventions [11]